AnalystsGavin Clark-Gartner
Gavin Clark-Gartner's Stock Forecasts

Analyst Ranking
Bottom 5%
#4927 out of 5134 analysts
Average Return
-7.82%
Win Rate
45%15 out of 33
Risk vs Reward
Poor
Good

Gavin Clark-Gartner's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Argenx SeARGX
+76.16%$354.13$623.82
2023-12-20 -
2024-12-20
Buy
Mind Medicine IncMNMD
+66.22%$7.43$12.35
2025-01-27 -
2025-12-05
Buy
Argenx SeARGX
+53.92%$596.74$918.50
2024-11-20 -
2025-11-20
Buy
Mirum Pharmaceuticals IncMIRM
+50.04%$39.87$59.82
2024-08-07 -
2025-08-07
Buy
C4 Therapeutics IncCCCC
+48.96%$3.35$4.99
2023-05-29 -
2024-05-29
Buy

Gavin Clark-Gartner Analyst Color

Get additional color on Gavin Clark-Gartner's coverage of popular stocks

Gavin Clark-Gartner's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Evommune IncEVMN
1Buy$40.00+82.65%Initiates Coverage On
5 days ago
Forte Biosciences IncFBRX
1Buy$65.00+226.14%Initiates Coverage On
11 days ago
Argenx SeARGX
5Buy$910.00+0.98%Maintains
a month ago
Jasper Therapeutics IncJSPR
4Buy$14.00+718.71%Maintains
2 months ago
Abbvie IncABBV
5Buy$222.00-1.80%Maintains
2 months ago
Mirum Pharmaceuticals IncMIRM
3Buy$89.00+29.96%Maintains
4 months ago
Proqr Therapeutics NvPRQR
1Buy$5.00+139.23%Initiates Coverage On
7 months ago
Mind Medicine IncMNMD
1Buy$23.00+86.23%Initiates Coverage On
10 months ago
Cabaletta Bio IncCABA
2Hold$6.00+135.29%Downgrades
a year ago
Sarepta Therapeutics IncSRPT
9Buy$170.00N/AMaintains
a year ago
Foghorn Therapeutics IncFHTX
1Buy$20.00N/AInitiates Coverage On
a year ago
Krystal Biotech IncKRYS
1Buy$206.00N/AMaintains
a year ago
Aclaris Therapeutics IncACRS
1Buy$22.00N/AInitiates Coverage On
2 years ago
C4 Therapeutics IncCCCC
1Buy$10.00N/AMaintains
3 years ago
Inhibrx IncINBX1
1Buy$60.00N/AMaintains
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.